The biotechnology sector, as measured by the XBI ETF, surged today following a strong quarterly report from Moderna (MRNA). The company significantly beat revenue and earnings expectations and raised its full-year 2026 revenue growth forecast from 10% to a range of 15-25%. This positive surprise from a major industry player has lifted investor sentiment across the biotech landscape. The news sent Moderna's stock up 10% in pre-market trading, leading the broader sector higher.
Biotech Sector Rallies on Strong Moderna Earnings and Outlook